回生口服液联合托泊替康治疗卵巢癌的临床研究

目的探讨采取回生口服液联合托泊替康治疗卵巢癌的临床效果。方法选取河南省人民医院于2016年2月—2017年2月收治的卵巢癌患者121例,随机分成对照组(60例)和治疗组(61例)。对照组患者静脉滴注注射用盐酸托泊替康,2.0 mg/m~2,1次/d,21 d为1个疗程,分别在每个疗程的第1、8、15天进行治疗。治疗组患者在对照组基础上口服回生口服液,10 m L/次,3次/d,21 d为1个疗程。两组患者均连续治疗3个疗程。观察两组患者临床疗效,比较治疗前后两组患者KPS和QDL评分,癌抗原125(CA-125)、IL-6和人附睾分泌蛋白4(HE4)水平及不良反应情况。结果治疗后,对照组客观缓解率为43.33%,疾病控制率为65.00%,均分别显著低于治疗组的60.66%和83.61%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者KPS评分和QDL评分均显著升高(P0.05);且治疗组患者各评分比对照组升高的更为明显(P0.05)。治疗后,两组患者CA-125水平明显升高,IL-6和HE4水平明显降低,同组比较差异具有统计学意义(P0.05);且治疗组患者CA-125、IL-6和HE4水平明显优于对照组(P0.05)。治疗期间,治疗组患者不良反应发生率为47.54%,显著高于对照组的25.00%,两组比较差异具有统计学意义(P0.05)。结论回生口服液联合托泊替康治疗卵巢癌患者临床疗效显著,不良反应发生率低,具有一定的临床推广应用价值。

Clinical study on Huisheng Oral Liquid combined with topotecan in treatment of ovarian cancer

Objective To explore the clinical effect of Huisheng Oral Liquid combined with topotecan in treatment of ovarian cancer. Methods Patients (121 cases) with ovarian cancer in Henan Province People''s Hospital from February 2016 to February 2017 were randomly divided into control (60 cases) and treatment (61 cases) based. Patients in the control group were iv administered with Topotecan Hydrochloride for injection, 2.0 mg/m², once daily, 21 d as a course of treatment, and they were treated on the 1st, 8th, and 15th day. Patients in the treatment group were po administered with Huisheng Oral Liquid on the basis of the control group, 10 mL/time, three times daily, and 21 d as a course of treatment. Patients in two groups were treated for 3 courses of treatment. After treatment, the clinical efficacy was evaluated, and the KPS and QDL scores, the CA-125, IL-6 and HE4 levels, the adverse reactions in two groups before and after treatment was compared. Results After treatment, the objective remission rate and disease control rate in the control group were 43.33% and 65.00%, which were significantly lower than 60.66% and 83.61% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the KPS and QDL scores in two groups were significantly increased (P < 0.05). And the scores in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the CA-125 level in two groups was significantly increased, but IL-6 and HE4 levels were significantly decreased, and there were differences in the same group (P < 0.05). And the CA-125, IL-6 and HE4 levels in the treatment group were significantly better than those in the control group (P < 0.05). During the treatment, the incidence of adverse reactions in the treatment group was 47.54%, which was significantly higher than 25.00% in the control group, with significant difference between two groups (P < 0.05). Conclusion Huisheng Oral Liquid combined with topotecan has significant clinical efficacy in treatment of ovarian cancer with lower adverse reactions incidence, which has a certain clinical application value.